Acelyrin, Inc. (NASDAQ:SLRN) CEO Sells $49,281.64 in Stock

Acelyrin, Inc. (NASDAQ:SLRN) CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the sale, the chief executive officer now directly owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. The trade was a 2.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Acelyrin Stock Performance

SLRN opened at $2.77 on Friday. The business has a 50 day moving average price of $2.27 and a 200 day moving average price of $3.83. Acelyrin, Inc. has a twelve month low of $1.85 and a twelve month high of $8.39. The firm has a market cap of $277.90 million, a P/E ratio of -1.13 and a beta of 1.25.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.07. As a group, analysts anticipate that Acelyrin, Inc. will post -2.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on SLRN. Citigroup lowered their price target on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Wells Fargo & Company lowered their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, HC Wainwright reduced their target price on Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Acelyrin has an average rating of “Hold” and an average price target of $9.60.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Acelyrin during the third quarter worth approximately $50,000. HighTower Advisors LLC acquired a new position in shares of Acelyrin during the third quarter worth approximately $50,000. XTX Topco Ltd acquired a new position in shares of Acelyrin during the fourth quarter worth approximately $33,000. 4WEALTH Advisors Inc. acquired a new position in shares of Acelyrin during the fourth quarter worth approximately $35,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Acelyrin during the fourth quarter worth approximately $36,000. 87.31% of the stock is currently owned by institutional investors and hedge funds.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.